What Is It?
The original non-steroidal SARM. Aryl-propionamide structure. Developed by GTx, Inc. in 2001. If YK-11 is the imposter in the SARM catalog — Ostarine is the prototype.
How Does It Work?
Tissue-selective androgen receptor agonism. Oral with a 24-hour half-life. Selectively targets muscle and bone over prostate tissue. Increases lean body mass (validated across 15+ trials) and improves bone mineral density.
Primary Benefits (research suggests)
- Lean body mass increases validated across 15+ trials
- Now in Phase 3 for AR+ breast cancer and as a muscle-preserving adjunct to GLP-1 weight loss drugs
- Potentially the most commercially relevant SARM application
Run the Numbers
Calculate your Ostarine dosing — capsule strength, daily totals, and protocol planning. Free, no login required.
Open the Calculator →The Honest Part
- The mildest SARM still isn't mild.
- Documented cholestatic jaundice cases.
- Suppresses testosterone.
- Not FDA-approved.
- WADA banned.
- Contaminated supply is rampant — Ryan Garcia's 2024 accidental ban is one example.
- For research purposes only.
Research Sources
Verified vendors offering this compound for research purposes. Use code ROCN10 for discounts. We may earn commissions from these links.
Track Ostarine in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →